BRPI0512547A - pirimidinas - Google Patents

pirimidinas

Info

Publication number
BRPI0512547A
BRPI0512547A BRPI0512547-2A BRPI0512547A BRPI0512547A BR PI0512547 A BRPI0512547 A BR PI0512547A BR PI0512547 A BRPI0512547 A BR PI0512547A BR PI0512547 A BRPI0512547 A BR PI0512547A
Authority
BR
Brazil
Prior art keywords
pyrimidines
akt
isoforms
formula
relates
Prior art date
Application number
BRPI0512547-2A
Other languages
English (en)
Inventor
Josef Stadlwieser
Ulrich Graedler
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of BRPI0512547A publication Critical patent/BRPI0512547A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

PIRIMIDINAS. A presente invenção refere-se a novos derivados de pirimidina que são inibidores eficazes de proteína quinases, em particular de uma ou mais isoformas da proteína quinase B/Akt.
BRPI0512547-2A 2004-06-28 2005-06-28 pirimidinas BRPI0512547A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103011 2004-06-28
EP05102355 2005-03-23
PCT/EP2005/053019 WO2006000589A1 (en) 2004-06-28 2005-06-28 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0512547A true BRPI0512547A (pt) 2008-03-25

Family

ID=34973043

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512547-2A BRPI0512547A (pt) 2004-06-28 2005-06-28 pirimidinas

Country Status (16)

Country Link
US (1) US7879853B2 (pt)
EP (1) EP1763526B1 (pt)
JP (1) JP5065017B2 (pt)
KR (1) KR20070027723A (pt)
CN (1) CN1972934A (pt)
AT (1) ATE434614T1 (pt)
AU (1) AU2005256659A1 (pt)
BR (1) BRPI0512547A (pt)
CA (1) CA2570552A1 (pt)
DE (1) DE602005015110D1 (pt)
ES (1) ES2328601T3 (pt)
IL (1) IL179883A0 (pt)
MX (1) MXPA06014747A (pt)
NO (1) NO20070334L (pt)
WO (1) WO2006000589A1 (pt)
ZA (1) ZA200609637B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6907921B2 (en) 1998-06-18 2005-06-21 3M Innovative Properties Company Microchanneled active fluid heat exchanger
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MY147628A (en) 2006-07-06 2012-12-31 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US20090012434A1 (en) * 2007-07-03 2009-01-08 Anderson Robert S Apparatus, method, and system to treat a volume of skin
EP2214486A4 (en) * 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
AU2012321091B2 (en) * 2011-10-28 2016-05-12 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9364476B2 (en) * 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
MA37472A1 (fr) * 2012-04-04 2016-09-30 Amgen Inc Composés hétérocycliques et leurs utilisations
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN103601675B (zh) * 2013-10-08 2015-10-28 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
CN103483250B (zh) * 2013-10-08 2015-07-22 南京复兴生物科技有限公司 一种5-氨甲基烟酸的制备方法
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN113509471B (zh) * 2021-07-19 2023-06-13 中国药科大学 Akt2抑制剂在制备治疗阿霉素引发心肌损伤药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (pt) * 1994-11-12 1997-12-01 Zeneca Ltd
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
EP1246823A1 (en) * 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
BR0113165A (pt) 2000-08-08 2003-07-15 Ortho Mcneil Pharm Inc Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
AR035967A1 (es) * 2001-05-18 2004-07-28 Altana Pharma Ag Un compuesto de piridilmetilaminopirimidina, un medicamento que lo comprende y el uso del mismo
US7183288B2 (en) 2001-11-01 2007-02-27 Herwig Josephus Margareta Janssen, legal representative Amide derivatives as glycogen synthase kinase 3-β inhibitors
EP1448556A1 (en) * 2001-11-01 2004-08-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7910586B2 (en) 2002-01-04 2011-03-22 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
AU2003295776B2 (en) 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
EP1709007A1 (en) 2004-01-22 2006-10-11 Altana Pharma AG N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors
EP1901747A2 (en) * 2005-05-25 2008-03-26 Ingenium Pharmaceuticals AG Pyrimidine-based cdk inhibitors for treating pain

Also Published As

Publication number Publication date
DE602005015110D1 (de) 2009-08-06
EP1763526A1 (en) 2007-03-21
JP5065017B2 (ja) 2012-10-31
US20070208034A1 (en) 2007-09-06
MXPA06014747A (es) 2007-02-16
WO2006000589A8 (en) 2006-11-16
JP2008504251A (ja) 2008-02-14
ES2328601T3 (es) 2009-11-16
US7879853B2 (en) 2011-02-01
CN1972934A (zh) 2007-05-30
IL179883A0 (en) 2007-05-15
WO2006000589A1 (en) 2006-01-05
NO20070334L (no) 2007-03-28
EP1763526B1 (en) 2009-06-24
KR20070027723A (ko) 2007-03-09
CA2570552A1 (en) 2006-01-05
AU2005256659A1 (en) 2006-01-05
ZA200609637B (en) 2008-08-27
ATE434614T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
BRPI0512547A (pt) pirimidinas
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
TW200801008A (en) Protein kinase inhibitors
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
ATE554087T1 (de) Neue kinaseinhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
ATE508126T1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
DK1567522T3 (da) Pyrimidinforbindelser
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
MX2008001538A (es) Aril piridinas y metodos para su uso.
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE: ALTANA PHARMA AG

B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AG (DE)

Free format text: TRANSFERIDO DE: NYCOMED GMBH

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.